Latest filings (excl ownership)
8-K
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
2 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
PRE 14A
Preliminary proxy
18 Apr 24
S-8
Registration of securities for employees
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
27 Mar 24
8-K
Patent for composition of matter and use of Infectimune® based influenza vaccines granted in the United States
13 Mar 24
8-K
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer
22 Jan 24
8-K
Other Events
4 Dec 23
8-K
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
28 Nov 23
S-8
Registration of securities for employees
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
14 Nov 23
8-K
Other Events
9 Nov 23
8-K
PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO
23 Oct 23
8-K
Other Events
11 Oct 23
8-K
Other Events
3 Oct 23
8-K
Other Events
3 Oct 23
8-K
Other Events
3 Oct 23
8-K
Other Events
2 Oct 23
8-K
PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies
20 Sep 23
8-K
Other Events
11 Sep 23
8-K
PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference
8 Sep 23
8-K
Other Events
18 Aug 23
8-K
Other Events
17 Aug 23
8-K
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial
14 Aug 23
8-K
PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update
14 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Other Events
25 Jul 23
8-K
Other Events
17 Jul 23
8-K
Departure of Directors or Certain Officers
17 Jul 23
8-K
PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301
11 Jul 23
8-K
Other Events
14 Jun 23
8-K
Other Events
14 Jun 23
ARS
2022 FY
Annual report to shareholders
2 Jun 23
DEFA14A
Additional proxy soliciting materials
2 Jun 23
DEF 14A
Definitive proxy
2 Jun 23
8-K
Other Events
1 Jun 23
Latest ownership filings
4
Stephan Toutain
2 May 24
3
Stephan Toutain
2 May 24
SC 13G
BlackRock Inc.
29 Jan 24
4
Kirk V. Shepard
23 Jan 24
3
Kirk V. Shepard
23 Jan 24
4
Lars Boesgaard
4 Dec 23
3
Lars Boesgaard
4 Dec 23
4
Gregory Gene Freitag
17 Jul 23
4
OTIS W BRAWLEY
17 Jul 23
4
Kamil Ali-Jackson
17 Jul 23
4
RICHARD SYKES
17 Jul 23
4
Stephen C. Glover
17 Jul 23
4
Ilian Iliev
17 Jul 23
4
Spencer D. Brown
6 Jan 23
4
MATTHEW C HILL
6 Jan 23
4
GREGORY CONN
6 Jan 23
4
FRANK BEDU-ADDO
6 Jan 23
4
LAUREN WOOD
6 Jan 23
4
FRANK BEDU-ADDO
2 Dec 22
4
Steve C Glover
29 Jun 22
4
Ilian Iliev
29 Jun 22
4
OTIS W BRAWLEY
29 Jun 22
4
Gregory Gene Freitag
29 Jun 22
4
RICHARD SYKES
29 Jun 22
4
Kamil Ali-Jackson
29 Jun 22
4
Spencer D. Brown
3 Jun 22
3
Spencer D. Brown
3 Jun 22
4
GREGORY CONN
20 Jan 22
4
FRANK BEDU-ADDO
20 Jan 22
4
LAUREN WOOD
20 Jan 22
4
MATTHEW C HILL
14 Dec 21
4
MATTHEW C HILL
20 Oct 21
3
MATTHEW C HILL
20 Oct 21
3
Janetta Trochimiuk
12 Oct 21
SC 13G/A
HIRSCHMAN ORIN
27 Aug 21
SC 13D/A
NETSCIENTIFIC PLC
21 Jun 21
4
DeLyle W Bloomquist
21 Jun 21
SC 13G
HIRSCHMAN ORIN
21 Jun 21
4
FRANK BEDU-ADDO
17 Jun 21
4
OTIS W BRAWLEY
17 Jun 21